Oppenheimer analyst Matthew Biegler raised the firm’s price target on Ideaya Biosciences to $26 from $22 and keeps an Outperform rating on the shares after the company announced the initiation of darovasertib’s Phase 2 trial in neoadjuvant and adjuvant uveal melanoma. The design of the trial appears to be consistent with the one proposed by management at its December R&D day, the analyst tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on IDYA:
- Ideaya Biosciences provides update on darovasertib trials
- Oppenheimer feels ‘a lot better’ about Ideaya’s darovasertib plan after talks
- Ideaya upside ‘even more likely’ after IND accepted, says Capital One
- Ideaya Biosciences announces FDA conclusion that its IDE161 trial may proceed
- Buy/Sell: Wall Street’s top 5 stock calls this week
